Latest Insider Transactions at Ideaya Biosciences, Inc. (IDYA)
This section provides a real-time view of insider transactions for Ideaya Biosciences, Inc. (IDYA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IDEAYA Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IDEAYA Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 22
2023
|
Jason Throne Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-100.0%
|
$11,500
$23.0 P/Share
|
|
May 22
2023
|
Jason Throne Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+50.0%
|
$3,500
$7.01 P/Share
|
|
Apr 13
2023
|
Paul A. Stone Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+26.84%
|
$32,000
$4.62 P/Share
|
|
Apr 12
2023
|
Yujiro S Hata President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,601
+1.68%
|
$46,404
$4.31 P/Share
|
|
Oct 04
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,500
-0.94%
|
$39,000
$26.24 P/Share
|
|
Oct 04
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+1.83%
|
$16,500
$11.08 P/Share
|
|
Sep 08
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,384
-6.33%
|
$307,368
$27.54 P/Share
|
|
Sep 08
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,384
+6.09%
|
$79,688
$7.7 P/Share
|
|
Sep 07
2021
|
Paul A. Stone Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,500
-16.19%
|
$67,500
$27.42 P/Share
|
|
Sep 07
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
116
-0.15%
|
$3,132
$27.46 P/Share
|
|
Sep 07
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
116
+0.15%
|
$464
$4.31 P/Share
|
|
Sep 02
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-11.26%
|
$250,000
$25.09 P/Share
|
|
Aug 09
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,500
-5.76%
|
$264,500
$23.24 P/Share
|
|
Aug 09
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+1.47%
|
$6,000
$4.31 P/Share
|
|
Jul 27
2021
|
Jason Throne Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$250,000
$25.17 P/Share
|
|
Jul 27
2021
|
Jason Throne Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$130,000
$13.34 P/Share
|
|
Jul 27
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-9.19%
|
$250,000
$25.15 P/Share
|
|
Jul 27
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+4.5%
|
$50,000
$5.62 P/Share
|
|
Jul 06
2021
|
Jason Throne Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,000
-70.5%
|
$220,000
$22.42 P/Share
|
|
Jul 06
2021
|
Jason Throne Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+34.64%
|
$100,000
$10.18 P/Share
|
|
Jul 06
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,500
-0.75%
|
$33,000
$22.48 P/Share
|
|
Jul 06
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+1.47%
|
$9,000
$6.92 P/Share
|
|
Jun 17
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,893
-3.79%
|
$85,646
$22.49 P/Share
|
|
Jun 17
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,893
+3.65%
|
$23,358
$6.92 P/Share
|
|
Jun 16
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,107
-1.11%
|
$24,354
$22.47 P/Share
|
|
Jun 16
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,107
+1.1%
|
$6,642
$6.92 P/Share
|
|
Jun 07
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,500
-1.5%
|
$30,000
$20.22 P/Share
|
|
Jun 07
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+1.47%
|
$9,000
$6.92 P/Share
|
|
May 28
2021
|
Paul A. Stone Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
859
+5.86%
|
$9,449
$11.36 P/Share
|
|
May 11
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.82%
|
$100,000
$20.22 P/Share
|
|
May 11
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.6%
|
$30,000
$6.92 P/Share
|
|
Feb 10
2021
|
Mark Lackner SVP, Head of Biology |
SELL
Open market or private sale
|
Direct |
596
-100.0%
|
$12,516
$21.0 P/Share
|
|
Feb 10
2021
|
Mark Lackner SVP, Head of Biology |
BUY
Exercise of conversion of derivative security
|
Direct |
596
+50.0%
|
$3,576
$6.98 P/Share
|
|
Feb 09
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.82%
|
$100,000
$20.74 P/Share
|
|
Feb 09
2021
|
Michael P. Dillon SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.6%
|
$30,000
$6.92 P/Share
|
|
Feb 09
2021
|
Mark Lackner SVP, Head of Biology |
SELL
Open market or private sale
|
Direct |
1,104
-100.0%
|
$23,184
$21.05 P/Share
|
|
Feb 09
2021
|
Mark Lackner SVP, Head of Biology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,104
+50.0%
|
$6,624
$6.98 P/Share
|
|
Feb 08
2021
|
Mark Lackner SVP, Head of Biology |
SELL
Open market or private sale
|
Direct |
300
-66.67%
|
$6,300
$21.01 P/Share
|
|
Feb 08
2021
|
Mark Lackner SVP, Head of Biology |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+50.0%
|
$1,800
$6.98 P/Share
|
|
Feb 02
2021
|
Bvf Partners L P |
SELL
Open market or private sale
|
Direct |
46,409
-1.58%
|
$835,362
$18.0 P/Share
|
|
Jan 26
2021
|
Mark Lackner SVP, Head of Biology |
SELL
Open market or private sale
|
Direct |
2,501
-84.01%
|
$45,018
$18.55 P/Share
|
|
Jan 26
2021
|
Mark Lackner SVP, Head of Biology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+26.23%
|
$7,500
$5.8 P/Share
|
|
Dec 22
2020
|
Yujiro S Hata President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+1.19%
|
$32,000
$4.31 P/Share
|
|
Dec 18
2020
|
Michael P. Dillon SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,750
+7.27%
|
$31,000
$4.31 P/Share
|
|
Dec 11
2020
|
Paul A. Stone Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
444
+2.79%
|
-
|
|
Dec 04
2020
|
Jason Throne Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,979
-60.11%
|
$29,685
$15.1 P/Share
|
|
Nov 11
2020
|
5 Am Ventures Iv, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
800,000
-23.1%
|
$10,400,000
$13.66 P/Share
|
|
Jun 30
2020
|
Bvf Partners L P |
BUY
Open market or private purchase
|
Direct |
2,531
+0.07%
|
$32,903
$13.32 P/Share
|
|
Jun 22
2020
|
Bvf Partners L P |
BUY
Open market or private purchase
|
Direct |
19,732
+0.61%
|
$256,516
$13.93 P/Share
|
|
Jun 19
2020
|
Bvf Partners L P |
BUY
Open market or private purchase
|
Direct |
98,264
+3.01%
|
$1,375,696
$14.39 P/Share
|